Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11.69% in the 7MM, Projects DelveInsight

LAS VEGAS, May 3, 2021 /PRNewswire/ -- DelveInsight's Biliary Tract Cancers (BTC) Market Insights report lays forward comprehensive insights into current treatment practices, emerging drugs, BTC market share of the individual therapies, current and forecasted BTC market size from 2018 to 2030 in the 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the pointers from the Biliary Tract Cancers Market report are:

• DelveInsight's epidemiological analysis estimates that the total Biliary Tract Cancers (BTC) incidence was 73,442 in 2020 in the 7MM. In 2018, the incident cases BTC in the US was found to be 17,023 which as per DelveInsight's analysts, shall increase during the forecast period, due to increasing obesity and an increase in other related etiological risk factors. Among these cases, Cholangiocarcinoma accounts for nearly 5,527 cases in the US in 2018. In the US, Moreover, analysts believe that Cholangiocarcinoma incidence is expected to increase further during the study period 2018-30. 
• Key pharmaceutical companies making an impact in the BTC market landscape include Agios Pharmaceuticals, Incyte Corporation, QED Therapeutics, Delcath Systems, Bayer, Loxo Oncology, Hoffmann-La Roche, Basilea Pharmaceutica, Janssen Research and Development, among several others. 
• Major BTC pipeline therapies expected to get launched in the forecast period 2021-30 are Ivosidenib (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Infigratinib (QED Therapeutics), Melphalan Hydrochloride (Delcath Systems), Regorafenib (Bayer), Larotrectinib (Loxo Oncology), Entrectinib (Hoffmann-La Roche), Derazantinib (Basilea Pharmaceutica) and Erdafitinib (Janssen Research and Development).
• The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing. 
• Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum. 

Get in touch for a holistic view of the Biliary Tract Cancers Market 

The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market's underlying potential, and plans strategically to tackle market risks.

Biliary Tract Cancers are an uncommon and highly fatal kind of malignancy. It is composed of three main different entities; Gall Bladder Carcinoma (GBC), Intrahepatic Cholangiocarcinoma (iCC) and Extrahepatic Cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation.

DelveInsight estimates show that Japan accounted for the highest market size of BTC as compared to EU5 and the US. 

DelveInsight estimates that the BTC incidence varies on the basis of subtypes that include Cholangiocarcinoma (Intrahepatic CCA and Extrahepatic CCA), Gall Bladder cases.

BTC Market Insights Report provides historical as well as forecasted BTC epidemiological analysis for the study period 2018-30 in the 7MM (the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan) segmented into:

• Incident Cases of Biliary Tract Cancers
• Subtype specific Incident Cases of Biliary Tract Cancers
• Incident Cases of Cholangiocarcinoma
• Type-specific Incident Cases of Cholangiocarcinoma
• Age-specific Incident Cases of Biliary Tract Cancers
• Mutation-specific Incident Cases of Biliary Tract Cancers

Biliary Tract Cancers Market Insights 

The Biliary Tract Cancers treatment market is primarily occupied by surgery with adjuvant chemotherapy and chemoradiation therapy. However, surgical treatments are the only available curative therapeutic options. Whereas for advanced and metastatic tumors, systemic chemotherapy is the only available option. As per the ESMO guidelines, adjuvant therapy (radiotherapy, chemo-radiotherapy, or chemotherapy alone) may be offered to patients to understand that the evidence base is weak and only after a risk-benefit assessment; participation in clinical trials should be encouraged.

However, with the majority of BTC patients diagnosed at later stages of cancer and nearly more than one-fourth of patients who during explorative laparotomy are found to be unresectable and higher rates of recurrence, there is a dire need for alternative standard curative options in the BTC market. Moreover, there is no established second-line systemic therapy that can be given after the tumor progression after first-due to the difficulty in mapping the true incidence of BTC ascribed to its classification. 

Drop by to learn more about the future market trends @ Biliary Tract Cancers Market Landscape and Forecast 

Nevertheless, several pharmaceutical companies are working in the BTC market domain to dynamically transform the market outlook and bring novel curative approaches to patients. In 2020, Incyte Corporation had its pemigatinib approved as the first targeted therapy for adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma. Pharma companies expected to follow the lead include Agios Pharmaceuticals, Incyte Corporation, QED Therapeutics, Delcath Systems, Bayer, Loxo Oncology, Hoffmann-La Roche, Basilea Pharmaceutica, Janssen Research and Development, and several others. 

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

Biliary Tract Cancers Market Forecast 

The Biliary Tract Cancer therapeutic landscape has undoubtedly expanded over the past few years, with a combined approach comprising chemotherapy, loco-regional treatment, and immunotherapy proving to be promising therapies. Extensive R&D to understand complicated pathophysiology has helped uncover the key role of pathways and mutations such as whole-exome and next next-generation sequencing. 

Moreover, increasing cognizance about different mutations, pathways, and other regimens has shifted the focus to the curable treatment options with emerging candidates that will enterprise the growth of the global market. The Biliary Tract Cancer market is also witnessing an increase in the investment in the R&D of drugs giving birth to a rich BTC pipeline. 

However, obstacles such as the rarity and difficulty in getting good diagnostic samples, accurate non-invasive biomarkers for the diagnosis, high heterogeneity and chemo-resistance of BTC, and the cost of the targeted therapies and immunotherapies are the current limitations in the BTC market share growth. 

Biliary Tract Cancers Pipeline Therapies and Key Pharma Companies 

• Ivosidenib: Agios Pharmaceuticals
• Pemigatinib: Incyte Corporation
• Infigratinib: QED Therapeutics
• Melphalan Hydrochloride: Delcath Systems
• Regorafenib: Bayer
• Larotrectinib: Loxo Oncology
• Entrectinib: Hoffmann-La Roche
• Derazantinib: Basilea Pharmaceutica
• Erdafitinib: Janssen Research and Development

Discuss the evolving trends of market landscape @ Biliary Tract Cancers Market and Epidemiological Forecast 

Scope of the Report 

Coverage: 7MM (the US, EU5, and Japan)

Study Period: 2018-30

Key Companies: Agios Pharmaceuticals, Incyte Corporation, QED Therapeutics, Delcath Systems, Bayer, Loxo Oncology, Hoffmann-La Roche, Basilea Pharmaceutica, Janssen Research and Development, and others.

Key Biliary Tract Cancer Pipeline Therapies: Ivosidenib, Pemigatinib, Infigratinib, Melphalan Hydrochloride, Regorafenib, Larotrectinib, Entrectinib, Derazantinib, Erdafitinib, and others.

Biliary Tract Cancer Market Segmentation: By Geography, By BTC Therapies

Analysis: Comparative and conjoint analysis of BTC emerging therapies

Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies
KOL's Views
Analyst's Views

Learn more about the report scope @ Biliary Tract Cancers Market Insights and Unfolding Future Trends 

Table of Contents 

Get in touch with us to know BTC Market Landscape and Key Companies Involved 

Browse Through Related Reports and Posts

Read more about Rare Cancers Market @ Rare Cancers Market Insights, and Forecast Analysis 

Know more about Angelman Syndrome Medications

ABSSSI Pipeline Therapies

A comprehensive description of treatment and key companies such as Innovation Pharmaceuticals, Motif Bio, Basilea Pharmaceutica, Debiopharm, Destiny Pharma, KBP Biosciences, MicuRx Pharmaceuticals, and several others in the ABSSSI market.

Head And Neck Cancer Market

Get comprehensive insights into epidemiology, key pipeline therapies, and pharma companies including Merck, Sinocelltech, GlaxoSmithKline, Hoffmann-La Roche, AstraZeneca, AVEO Pharmaceuticals, and others working in the Head and Neck market. 

Advanced Liver Cancer Market

Get comprehensive insights into epidemiology, key pipeline therapies, and pharma companies including Siranomics, Novartis, Yiviva, Eisai, CAS Lamvac Biotech, Benhealth Biopharmaceutical, Chia Tai Tianqing Pharmaceutical, Surface Oncology, Zai Lab (Shanghai), Can-Fite Biopharma, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, SignalRX Pharmaceuticals, Carsgen Therapeutics, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, Leap Therapeutics, Eureka Therapeutics, and others. 

Anal Cancer Market

DelveInsight's "Anal Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Cancer Cachexia Market

Get comprehensive insights into epidemiology, key pipeline therapies their approvals such as anamorelin fda approval, and pharma companies including Helsinn Therapeutics/Ono Pharmaceutical, AEterna Zentaris, Actimed Therapeutics/PsiOxus Therapeutics, Pfizer, XBiotech/Janssen Pharmaceutical, Cannabics Pharmaceuticals,  NGM Bio, Artelo BIOSCIENCES, and many more. 

Prostate Cancer Market 

Get comprehensive insights into epidemiology, key pipeline therapies, and pharma companies including AstraZeneca/Merck Sharp & Dohme (Lynparza), Bristol-Myers Squibb (Opdivo), Novartis (Lutathera), Myovant Sciences (Relugolix), Janssen Research & Development (Niraparib), Hinova Pharmaceuticals USA (HC-1119), Hoffmann-La Roche (Ipatasertib), Pfizer/Astellas Pharma (Talazoparib), Clovis Oncology (Rucaparib), Advantagene or Candel Therapeutics (ProstAtak), and Merck Sharp & Dohme (Keytruda) and several others. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Expand your Pharma and healthcare business and presence throughout the world with DelveInsight's Consulting and Merger & Acquisition services. 

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg